Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3085002 | 1.00 | CHRNA7 (0.43) | CHRNA7LSSCHRM2CHRM1MCHR1 | |
| SCHEMBL1020348 | 1.00 | CHRNA7 (0.43) | CHRNA7LSSCHRM2CHRM1MCHR1 | |
| SCHEMBL1018315 | 0.91 | CHRNA7 (0.44) | CHRNA7LSS | |
| SCHEMBL1019569 | 0.90 | CHRNA7 (0.44) | CHRNA7LSS | |
| SCHEMBL1017804 | 0.86 | CHRNA7 (0.44) | CHRNA7LSSCHRM2CHRM1 | |
| SCHEMBL1019786 | 0.86 | CHRNA7 (0.44) | CHRNA7LSSCHRM2CHRM1 | |
| SCHEMBL3065850 | 0.86 | CHRNA7 (0.44) | CHRNA7LSSCHRM2CHRM1 | |
| SCHEMBL1018510 | 0.86 | LSS (0.48) | CHRNA7LSSCHRM2CHRM1MCHR1 | |
| SCHEMBL3080565 | 0.86 | CHRNA7 (0.44) | CHRNA7LSSCHRM2CHRM1 | |
| SCHEMBL3084805 | 0.86 | CHRNA7 (0.46) | CHRNA7CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227869-A1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2010-09-09 | — | — | US | claimed |
| EP-1987029-B1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH AS (DK) | 2010-01-13 | — | — | EP | claimed |
| EP-1987029-A1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2008-11-05 | — | — | EP | claimed |
| WO-2007093602-A1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2007-08-23 | — | — | WO | claimed |
| US-20100227869-A1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2010-09-09 | — | — | US | disclosed |
| EP-1987029-B1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH AS (DK) | 2010-01-13 | — | — | EP | disclosed |
| EP-1987029-A1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093602-A1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227869-A1 | ENANTIOPURE QUINUCLIDINYLOXY PYRIDAZINES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA5, CHRNA6, CHRNA2 | CHRNA7 7/4885LSS 2595/4885CHRM2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.